A de novo theranostic nanomedicine composed of PEGylated graphene oxide and gold nanoparticles for cancer therapy

Samadian, Hadi; Mohammad‐Rezaei, Rahim; Jahanban‐Esfahlan, Rana; Massoumi, Bakhshali; Abbasian, Mojtaba; Jafarizad, Abbas; Jaymand, Mehdi

doi:10.1557/jmr.2020.3

Cited by 40 publications

(16 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Table S1 reports the title, first author, journal, date of publication, and DOI for the seventeen publications [44,[64][65][66][67][68][69][70][71][72][73][74][75][76][77][78][79]. Those included were published in sixteen scientific journals ranging from 2008 to 2021.…”

Section: Methodsmentioning

confidence: 99%

“…Of these, 65% were published within the last five years (since 2016), highlighting the advancement of research and research interest in the area of graphene nanomaterials for drug delivery. Table S1 reports the title, first author, journal, date of publication, and DOI for the seventeen publications [43,[63][64][65][66][67][68][69][70][71][72][73][74][75][76][77][78]. Those included were published in sixteen scientific journals ranging from 2008 to 2021.…”

Section: Methodsmentioning

confidence: 99%

“…The GO-TD-Fe 3 O 4 @PEG composite, records a high DLE of DOX at 92.6% and a high cumulative release of 97.3% at pH 5.0 after 72 h, suggesting high delivery efficiency [67]. Whereas GO-PEG-FA/GNPs/DOX has a high loading efficiency of 84%, only ~43% of that loaded drug is released at pH 4.0 after 295 h [76]. Finally, NGO-PEG-DA/DOX has a reasonably low loading efficiency of 50% and only releases 31.4% of that loaded drug after 24 h [65], which theoretically means that if 1 mg of DOX was loaded onto the nanohybrid, only 0.157 mg would reach the intended target.…”

Section: Clinical Relevancementioning

confidence: 99%

See 2 more Smart Citations

Drug Release Kinetics of DOX-Loaded Graphene-Based Nanocarriers for Ovarian and Breast Cancer Therapeutics

2021

View full text Add to dashboard Cite

Cancer remains one of the leading causes of death worldwide despite extensive efforts at developing curative treatments. Chemotherapy, one of the most common forms of treatment, lacks specificity and can induce collateral damages to healthy surrounding tissues/cells and elicit off-target toxic side effects. The carbon-based nanomaterial graphene, can load aromatic drugs with high efficiency, has good biocompatibility, and can be easily functionalised with targeting ligands, antibodies, and biomolecules to increase the accuracy of targeting specific areas; graphene has therefore been explored as a nanocarrier for classical chemotherapy drugs. In this work, seventeen publications that report the release of doxorubicin (DOX) from 2D graphene-based nanohybrids (graphene oxide and reduced graphene oxide) for the treatment of breast and ovarian cancers have been identified based on a range of inclusion and exclusion criteria. To aid in the clinical translation of proof-of-concept studies, this work identifies the pre-clinical experimental protocols and analyses the release kinetics of these publications. Fifteen of the papers utilised a change in pH as the stimulus for drug release, and two utilised either near infrared (NIR) or ultrasound as the stimulus. The extracted drug release data from these publications were fit to four known kinetic models. It was found that the majority of these data best fit the Weibull kinetic model. The agreement between the kinetic data in previously published literature provides a predictable estimation of DOX release from graphene-based nanocarriers. This study demonstrates the potential conjugation of graphene and DOX in drug delivery applications, and this knowledge can help improve to the design and formulation of future graphene-based nanocarriers. In addition, the use of further experimental testing and the standardisation of experimental protocols will be beneficial for future work. The incorporation of computational modelling prior to pre-clinical testing will also aid in the development of controlled and sustained DOX release systems that offer efficient and efficacious results.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Clinical Relevancementioning

confidence: 99%

See 1 more Smart Citation

Drug Release Kinetics of DOX-Loaded Graphene-Based Nanocarriers for Ovarian and Breast Cancer Therapeutics

2021

View full text Add to dashboard Cite

show abstract

“…Samadian et al [ 52 ] designed a PEG and folic acid (FA)-functionalized graphene oxide (GO) decorated with Au NPs (GO–PEG–FA/GN). The developed hybrid system encapsulated DOX, and its anti-cancer efficacy was tested using human breast cancer (MCF-7) cells.…”

Section: Ph-responsive Nanocarriers For Cancer Therapymentioning

confidence: 99%

pH-Responsive Nanocarriers in Cancer Therapy

et al. 2022

View full text Add to dashboard Cite

A number of promising nano-sized particles (nanoparticles) have been developed to conquer the limitations of conventional chemotherapy. One of the most promising methods is stimuli-responsive nanoparticles because they enable the safe delivery of the drugs while controlling their release at the tumor sites. Different intrinsic and extrinsic stimuli can be used to trigger drug release such as temperature, redox, ultrasound, magnetic field, and pH. The intracellular pH of solid tumors is maintained below the extracellular pH. Thus, pH-sensitive nanoparticles are highly efficient in delivering drugs to tumors compared to conventional nanoparticles. This review provides a survey of the different strategies used to develop pH-sensitive nanoparticles used in cancer therapy.

show abstract

“…PEG is usually used to enhance the stability, solubility, and immune escape of these gold nanoparticles. Although PEGylation has its own disadvantages, on repetitive administration and in the presence of anti-PEG bodies, therapeutic efficacy is reduced [97]. Whereas, red blood cell membranes have a better immune escape ability because the proteins present in them act like immunomodulatory antigens to escape phagocytosis.…”

Section: Nanostars Coated With Rbc and Platelet Membrane For Drug Delivery In Skin Cancermentioning

confidence: 99%

Recent Advances and Implication of Bioengineered Nanomaterials in Cancer Theranostics

et al. 2021

View full text Add to dashboard Cite

Cancer is one of the most common causes of death and affects millions of lives every year. In addition to non-infectious carcinogens, infectious agents contribute significantly to increased incidence of several cancers. Several therapeutic techniques have been used for the treatment of such cancers. Recently, nanotechnology has emerged to advance the diagnosis, imaging, and therapeutics of various cancer types. Nanomaterials have multiple advantages over other materials due to their small size and high surface area, which allow retention and controlled drug release to improve the anti-cancer property. Most cancer therapies have been known to damage healthy cells due to poor specificity, which can be avoided by using nanosized particles. Nanomaterials can be combined with various types of biomaterials to make it less toxic and improve its biocompatibility. Based on these properties, several nanomaterials have been developed which possess excellent anti-cancer efficacy potential and improved diagnosis. This review presents the latest update on novel nanomaterials used to improve the diagnostic and therapeutic of pathogen-associated and non-pathogenic cancers. We further highlighted mechanistic insights into their mode of action, improved features, and limitations.

show abstract

A de novo theranostic nanomedicine composed of PEGylated graphene oxide and gold nanoparticles for cancer therapy

Abstract: Abstract

Cited by 40 publications

References 36 publications

Drug Release Kinetics of DOX-Loaded Graphene-Based Nanocarriers for Ovarian and Breast Cancer Therapeutics

Drug Release Kinetics of DOX-Loaded Graphene-Based Nanocarriers for Ovarian and Breast Cancer Therapeutics

pH-Responsive Nanocarriers in Cancer Therapy

Recent Advances and Implication of Bioengineered Nanomaterials in Cancer Theranostics

Contact Info

Product

Resources

About